Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Dana Pizzuti Sells 2,515 Shares

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) insider Dana Pizzuti sold 2,515 shares of the company’s stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $34.20, for a total value of $86,013.00. Following the completion of the sale, the insider now owns 72,233 shares of the company’s stock, valued at approximately $2,470,368.60. The trade was a 3.36 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Dana Pizzuti also recently made the following trade(s):

• On Monday, February 3rd, Dana Pizzuti sold 5,000 shares of Crinetics Pharmaceuticals stock. The stock was sold at an average price of $39.07, for a total transaction of $195,350.00.

Crinetics Pharmaceuticals Stock Performance

NASDAQ CRNX opened at $34.42 on Friday. Crinetics Pharmaceuticals, Inc. has a fifty-two week low of $31.84 and a fifty-two week high of $62.53. The company has a market cap of $3.20 billion, a P/E ratio of -9.23 and a beta of 0.58. The business’s 50 day moving average price is $36.22 and its 200-day moving average price is $48.13.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last released its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. As a group, equities analysts predict that Crinetics Pharmaceuticals, Inc. will post -3.73 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on CRNX shares. Jefferies Financial Group upgraded shares of Crinetics Pharmaceuticals from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a research note on Wednesday, January 22nd. JMP Securities restated a “market outperform” rating and set a $87.00 target price on shares of Crinetics Pharmaceuticals in a research report on Monday, December 16th. Wolfe Research began coverage on shares of Crinetics Pharmaceuticals in a research note on Tuesday, February 4th. They set a “peer perform” rating for the company. TD Cowen initiated coverage on shares of Crinetics Pharmaceuticals in a research note on Tuesday, February 11th. They issued a “buy” rating on the stock. Finally, HC Wainwright restated a “buy” rating and set a $81.00 price objective on shares of Crinetics Pharmaceuticals in a research report on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, Crinetics Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $74.30.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Venturi Wealth Management LLC bought a new position in Crinetics Pharmaceuticals in the fourth quarter worth approximately $41,000. State of Wyoming purchased a new position in shares of Crinetics Pharmaceuticals in the fourth quarter worth $50,000. Headlands Technologies LLC acquired a new stake in shares of Crinetics Pharmaceuticals during the fourth quarter worth $52,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of Crinetics Pharmaceuticals during the fourth quarter valued at $66,000. Finally, GF Fund Management CO. LTD. acquired a new position in shares of Crinetics Pharmaceuticals in the 4th quarter valued at $100,000. 98.51% of the stock is currently owned by hedge funds and other institutional investors.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.